MRNA Earnings History
Moderna, Inc. (MRNA) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $20.01B, listed on NASDAQ, employing roughly 5,800 people, carrying a beta of 1.06 to the broader market. Moderna, Inc. Led by Stéphane Bancel, public since 2018-12-07.
Moderna, Inc. has beat EPS estimates in 5 of the last 6 quarters.
| Date | EPS Est. | EPS Actual | Surprise | Revenue Est. | Revenue Actual |
|---|---|---|---|---|---|
| Jul 31, 2026 | -2.09 | N/A | N/A | $98.3M | N/A |
| May 1, 2026 | -3.02 | -1.18 | N/A | $236.4M | $389.0M |
| Feb 13, 2026 | -2.54 | -2.11 | N/A | $635.2M | $678.0M |
| Nov 6, 2025 | -1.87 | -0.51 | N/A | $920.9M | $1.02B |
| Aug 1, 2025 | -2.99 | -2.13 | N/A | $893.3M | $142.0M |
| May 1, 2025 | -2.92 | -2.52 | N/A | $116.7M | $107.0M |
What MRNA's Earnings History Tells Options Traders
Moderna, Inc. has a strong beat history (5 beats in 6 reports). Consistent beat-rate patterns typically inflate pre-event implied volatility and produce a sharp IV-crush after the print, conditions that favor pre-earnings short-vol structures when IV rank is elevated. Beat rate is one input to event-driven sizing; pair it with the implied-vs-realized volatility view, the current IV rank, and the put-call skew going into the print. Surprise magnitude matters as much as direction - an in-line beat with conservative guidance can produce a larger negative move than a missed quarter with raised forward guidance. The earnings table above shows the most recent six reported quarters; for the full multi-year history including revenue growth trajectory and EPS guidance trends, the per-ticker fundamentals view aggregates the underlying GAAP filings.
How Earnings Drive MRNA Options Pricing
Earnings events are the largest single driver of single-name implied volatility in equity options markets. Pre-event, IV inflates over the two-to-three week run-up as the binary uncertainty of the print compounds; the IV rank typically peaks the day before the announcement. Post-event, IV crushes back toward the realized-volatility baseline as uncertainty resolves. The magnitude of the crush depends on how stretched pre-event IV was relative to the eventual realized move - an oversized pre-event IV with an undersized realized move produces the cleanest premium-selling outcome, while a stretched IV that still under-prices a tail move on the print produces the cleanest long-vol outcome.
The catalyst calendar for MRNA matters beyond the headline EPS surprise. Forward guidance revisions, capital-allocation changes (dividend hikes, buyback authorizations, M&A announcements), and segment-level performance discussions can drive larger post-event moves than the headline beat or miss. Pair the earnings beat-rate read above with the upcoming-event calendar and the IV-rank view to size pre-event and post-event positioning; for short-vol structures the goal is to be long premium-rich and to harvest the IV crush, while for long-vol structures the goal is to own gamma cheap into a regime where the realized move is likely to exceed the implied move.
Frequently asked MRNA earnings questions
- How often does MRNA beat earnings estimates?
- Moderna, Inc. (MRNA) has beat consensus EPS estimates in 5 of the last 6 quarters. The table above shows estimate, actual, surprise percent, and revenue figures per quarter. Beat-rate matters less than the *pattern* of beats and misses: a name with a consistent beat history sees implied-vol expansion ahead of the print and a sharp IV crush after.
- What was MRNA's last reported earnings?
- The most recent reported quarter is Jul 31, 2026. Revenue, EPS, and prior-quarter comparisons are in the table above. Subsequent estimates and analyst-revisions live on the analyst-ratings page.
- How do MRNA earnings drive options pricing?
- Earnings events are the single largest driver of single-name implied volatility in equity options markets. Pre-event, IV inflates as the market prices the binary outcome (beat / miss / guidance change). Post-event, IV crushes as uncertainty resolves. The size of the crush is a function of how stretched pre-event IV was relative to the realized move: an oversized pre-event IV with an undersized move produces the cleanest premium-selling result. Pair MRNA earnings history with the implied-vs-realized volatility view to size pre-event positioning.
- When does MRNA report next?
- Next-quarter earnings dates are typically announced by the company 3-6 weeks ahead. Check the earnings-calendar page or company investor-relations site for the confirmed date. Pre-event IV typically begins building 2-3 weeks before the announcement and peaks the day before.